Biocept to Participate in Three Virtual Investment Conferences in March
Biocept, Inc. (Nasdaq: BIOC) announces participation in three virtual investment conferences in March 2021. CEO Michael Nall will engage at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, the 33rd Annual Roth Conference from March 15-17, and the Maxim 2021 Emerging Growth Virtual Conference on March 17-19. Biocept aims to advance its neuro-oncology initiative while maintaining its COVID-19 RT-PCR testing efforts, having processed over 300,000 samples since June 2020. The company is expanding its testing portfolio in collaboration with Aegea Biotechnologies.
- None.
- None.
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in three upcoming virtual investment conferences:
- H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. Biocept will hold virtual investor meetings. Investors can request a meeting by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here.
- 33rd Annual Roth Conference being held March 15-17, 2021. Biocept will hold virtual investor meetings. Investors interested in arranging a virtual meeting should contact their Roth Capital Partners sales representative or LHA Investor Relations. A webcast of Biocept’s presentation has been pre-recorded and is available on the Company’s website here. Roth Conference information is available here.
- Maxim 2021 Emerging Growth Virtual Conference being held March 17-19, 2021. Biocept will participate in a fireside chat hosted by Maxim Group Senior Managing Director Jason McCarthy, Ph.D. on Friday, March 19 at 1:30 p.m. Eastern time. Investors can register for the conference here.
Biocept’s corporate presentation is available on the Company’s website here.
“Our presentations highlight progress with our neuro-oncology initiative and strategy to become the standard of care when diagnosing and monitoring the spread of cancer into the CNS,” said Mr. Nall. “While pursuing this goal, our team continues to serve our community and help fight the pandemic with COVID-19 RT-PCR testing, having now received more than 300,000 COVID-19 samples since June 2020. We are excited about the opportunity to expand our RT-PCR COVID-19 testing portfolio under our recently announced supply agreement with Aegea Biotechnologies to develop a differentiated, quantitative laboratory developed test (LDT).”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, including metastatic tumors involving lung, breast and the central nervous system. Biocept’s patented Target Selector™ technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity and specificity than most commercial assays. Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 PCR testing to support public health efforts during this unprecedented pandemic. For additional information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our ability to become standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the CNS, our ability to expand our RT-PCR COVID-19 testing portfolio under our recently announced supply agreement with Aegea Biotechnologies, and the ability of Biocept’s liquid biopsy technology to provide physicians with clinically actionable information, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC) on November 16, 2020. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005299/en/
FAQ
What conferences will Biocept participate in March 2021?
What is Biocept's focus in the upcoming investment conferences?
How many COVID-19 samples has Biocept processed?
What collaboration did Biocept announce regarding COVID-19 testing?
